Literature DB >> 8211671

Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications.

S M Deore1, S K Shrivastava, S J Supe, P S Viswanathan, K A Dinshaw.   

Abstract

A total of 203 patients with cancer of cervix stage IIIB, treated by radiation alone were analysed retrospectively for the incidence of late rectal and recto-sigmoid complications. The patients were treated with a combination of external irradiation and a single intracavitary insertion during January 1979 to December 1983. The external irradiation was randomised to deliver by four different fractionation regimens having dose per fraction of 2 Gy, 3 Gy, 4 Gy and 5.4 Gy. The doses for various fractionation regimens were matched using the time dose factors (TDF) model. 39 cases of late radiation induced rectal and recto-sigmoid complications were observed. The complication rate increased significantly (p < 0.05) with the size of dose per fraction. Using this clinical data an alpha/beta value of 3.87 +/- 0.74 Gy was estimated for late rectal and recto-sigmoid complications.

Entities:  

Mesh:

Year:  1993        PMID: 8211671

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  9 in total

Review 1.  Current status of intensity-modulated radiation therapy (IMRT).

Authors:  Kazuo Hatano; Hitoshi Araki; Mitsuhiro Sakai; Takashi Kodama; Naoki Tohyama; Tohru Kawachi; Masaharu Imazeki; Takayuki Shimizu; Tsutomu Iwase; Minoru Shinozuka; Hideyo Ishigaki
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

2.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

3.  Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients.

Authors:  Christos Nanos; Vasilios Souftas; Athanasios Zissimopoulos; Michael I Koukourakis
Journal:  Radiat Oncol J       Date:  2022-06-20

Review 4.  Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.

Authors:  Víctor Macías; Albert Biete
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

5.  Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy.

Authors:  V Macias; R Gonzalez Celador; C Marti-Macia; C Cigarral; L A Perez-Romasanta
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

6.  Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.

Authors:  Steven Gresswell; Rodney E Wegner; Day Werts; Ralph Miller; Russell Fuhrer
Journal:  Adv Radiat Oncol       Date:  2016-08-18

7.  Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data.

Authors:  Daniel L P Holyoake; Marianne Aznar; Somnath Mukherjee; Mike Partridge; Maria A Hawkins
Journal:  Radiother Oncol       Date:  2017-06-06       Impact factor: 6.280

Review 8.  Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas.

Authors:  Adnan Elhammali; Mukund Patel; Benjamin Weinberg; Vivek Verma; Jingxia Liu; Jeffrey R Olsen; Hiram A Gay
Journal:  Radiat Oncol       Date:  2015-09-04       Impact factor: 3.481

9.  Hyperfractionated abdominal reirradiation for gastrointestinal malignancies.

Authors:  Andrew Hunt; Prajnan Das; Bruce D Minsky; Eugene J Koay; Sunil Krishnan; Joseph M Herman; Cullen Taniguchi; Albert Koong; Grace L Smith; Emma B Holliday
Journal:  Radiat Oncol       Date:  2018-08-07       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.